CA3123393A1 - Deutetrabenazine for the treatment of dyskinesia in cerebral palsy - Google Patents

Deutetrabenazine for the treatment of dyskinesia in cerebral palsy Download PDF

Info

Publication number
CA3123393A1
CA3123393A1 CA3123393A CA3123393A CA3123393A1 CA 3123393 A1 CA3123393 A1 CA 3123393A1 CA 3123393 A CA3123393 A CA 3123393A CA 3123393 A CA3123393 A CA 3123393A CA 3123393 A1 CA3123393 A1 CA 3123393A1
Authority
CA
Canada
Prior art keywords
patient
baseline
deutetrabenazine
score
study
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3123393A
Other languages
English (en)
French (fr)
Inventor
Juha-Matti Savola
Mark Forrest Gordon
Frank Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auspex Pharmaceuticals Inc
Original Assignee
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspex Pharmaceuticals Inc filed Critical Auspex Pharmaceuticals Inc
Publication of CA3123393A1 publication Critical patent/CA3123393A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3123393A 2018-12-13 2019-12-13 Deutetrabenazine for the treatment of dyskinesia in cerebral palsy Pending CA3123393A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862779232P 2018-12-13 2018-12-13
US62/779,232 2018-12-13
US201962801450P 2019-02-05 2019-02-05
US62/801,450 2019-02-05
PCT/US2019/066150 WO2020123900A1 (en) 2018-12-13 2019-12-13 Deutetrabenazine for the treatment of dyskinesia in cerebral palsy

Publications (1)

Publication Number Publication Date
CA3123393A1 true CA3123393A1 (en) 2020-06-18

Family

ID=69173404

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3123393A Pending CA3123393A1 (en) 2018-12-13 2019-12-13 Deutetrabenazine for the treatment of dyskinesia in cerebral palsy

Country Status (15)

Country Link
US (3) US11324732B2 (enExample)
EP (1) EP3893876A1 (enExample)
JP (1) JP2022519007A (enExample)
KR (1) KR20210114946A (enExample)
CN (1) CN113395966A (enExample)
AU (1) AU2019395250A1 (enExample)
BR (1) BR112021011386A2 (enExample)
CA (1) CA3123393A1 (enExample)
CL (1) CL2021001554A1 (enExample)
IL (1) IL283920A (enExample)
MX (1) MX2021007063A (enExample)
SG (1) SG11202106344SA (enExample)
TW (1) TWI784220B (enExample)
WO (1) WO2020123900A1 (enExample)
ZA (1) ZA202104786B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210114946A (ko) * 2018-12-13 2021-09-24 오스펙스 파마슈티칼스, 인코포레이티드 뇌성마비에서의 운동이상증의 치료를 위한 듀테트라베나진
BR112023021257A2 (pt) * 2021-04-15 2023-12-12 Neurocrine Biosciences Inc Métodos para a administração combinada de deutetrabenzina e um cyp2d6
WO2022221551A1 (en) * 2021-04-15 2022-10-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
WO2024090922A1 (ko) 2022-10-24 2024-05-02 주식회사 디자인셀 줄기세포 배양액 및 상기로부터 분리된 세포외소포를 유효성분으로 포함하는 뇌신경계 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2972242A1 (en) * 2008-09-18 2010-04-22 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
AU2015200243B2 (en) * 2009-06-24 2016-09-29 Egalet Ltd Controlled release formulations
EP3351247A1 (en) * 2010-06-01 2018-07-25 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
EP4345100A3 (en) 2012-09-18 2024-04-10 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
AU2016229949B2 (en) 2015-03-06 2021-04-08 Auspex Pharmaceuticals Llc Methods for the treatment of abnormal involuntary movement disorders
PE20191819A1 (es) 2017-03-15 2019-12-27 Auspex Pharmaceuticals Inc Analogos de deutetrabenazina, su preparacion y uso
KR20210114946A (ko) * 2018-12-13 2021-09-24 오스펙스 파마슈티칼스, 인코포레이티드 뇌성마비에서의 운동이상증의 치료를 위한 듀테트라베나진

Also Published As

Publication number Publication date
US20200188371A1 (en) 2020-06-18
US20220409597A1 (en) 2022-12-29
CL2021001554A1 (es) 2022-02-11
WO2020123900A1 (en) 2020-06-18
EP3893876A1 (en) 2021-10-20
ZA202104786B (en) 2023-12-20
US20240082225A1 (en) 2024-03-14
CN113395966A (zh) 2021-09-14
US11324732B2 (en) 2022-05-10
IL283920A (en) 2021-07-29
AU2019395250A1 (en) 2021-07-29
TWI784220B (zh) 2022-11-21
MX2021007063A (es) 2021-12-10
JP2022519007A (ja) 2022-03-18
TW202034917A (zh) 2020-10-01
BR112021011386A2 (pt) 2021-08-31
SG11202106344SA (en) 2021-07-29
KR20210114946A (ko) 2021-09-24

Similar Documents

Publication Publication Date Title
ES2879631T3 (es) Pridopidina para el tratamiento de la enfermedad de Huntington
JP2025036702A (ja) 神経認知障害、慢性疼痛を治療し、炎症を低減させる方法
US20240082225A1 (en) Methods for the treatment of dyskinesia in cerebral palsy
US20230321007A1 (en) Pharmacokinetics of nmda receptor antagonists
US20110319384A1 (en) Pharmaceutical Compositions
US20210308115A1 (en) Pridopidine for treating huntington's disease
CN113825510A (zh) 使用氘化右美沙芬和奎尼丁治疗精神分裂症的阴性症状的方法
JP2024517937A (ja) Ｎｍｄａ受容体拮抗薬の副作用の低減
CN118555956A (zh) 用于治疗难治性抑郁症的赛洛西宾和辅助血清素再摄取抑制剂
WO2024145288A2 (en) Methods of administering r-ketamine
CN121013719A (zh) 治疗特发性震颤的方法
CN119654149A (zh) 用于在治疗抑郁障碍中使用的奥法地尔的皮下施用和给药方法
EA044015B1 (ru) Дейтетрабеназин для лечения дискинезии при церебральном параличе
US20250375417A1 (en) Orexin receptor 2 (ox2r) agonist for use in narcolepsy type 1 (nt1)
HK40060751A (en) Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine
EP4618973A1 (en) Methods of switching neuropsychiatric medications using ulotaront
EA046262B1 (ru) Уменьшение побочных эффектов антагонистов n-метил-d-аспартата (nmda)
BA A randomized, placebo-controlled crossover trial of phentermine-topiramate ER in patients with binge-eating disorder and bulimia nervosa
Chan et al. Basics of Psychopharmacological Management

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231106

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241206

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241206

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241206

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250129

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250529

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260226